Burning Rock Biotech (BNR) Invested Capital (2021 - 2023)

Burning Rock Biotech has reported Invested Capital over the past 3 years, most recently at $106.7 million for Q4 2023.

  • Quarterly results put Invested Capital at $106.7 million for Q4 2023, down 34.47% from a year ago — trailing twelve months through Dec 2023 was $106.7 million (down 34.47% YoY), and the annual figure for FY2023 was $108.2 million, down 37.27%.
  • Invested Capital for Q4 2023 was $106.7 million at Burning Rock Biotech, down from $162.9 million in the prior quarter.
  • Over the last five years, Invested Capital for BNR hit a ceiling of $289.0 million in Q4 2021 and a floor of $106.7 million in Q4 2023.
  • Median Invested Capital over the past 3 years was $162.9 million (2022), compared with a mean of $186.2 million.
  • Biggest five-year swings in Invested Capital: tumbled 43.64% in 2022 and later tumbled 34.47% in 2023.
  • Burning Rock Biotech's Invested Capital stood at $289.0 million in 2021, then plummeted by 43.64% to $162.9 million in 2022, then tumbled by 34.47% to $106.7 million in 2023.
  • The last three reported values for Invested Capital were $106.7 million (Q4 2023), $162.9 million (Q4 2022), and $289.0 million (Q4 2021) per Business Quant data.